Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy.
Journal: NEJM catalyst innovations in care delivery
Published: July 08, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026
Advancing Prostate Cancer Survivorship Through Transatlantic Consortium Science: The iCCaRE Initiative.
Journal: Cancer research communications
Published: February 25, 2026
Immunotherapy and Radiation for Clinical Perineural Invasion in Cutaneous Squamous Cell Carcinoma.
Journal: Cancers
Published: October 20, 2025
Sex and tumor location outcomes in Merkel cell carcinoma: A retrospective cohort study utilizing Mayo Clinic Platform.
Journal: Journal of the American Academy of Dermatology
Published: September 13, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 10, 2025
Development of a prostate cancer survivorship care toolkit for Black men with clinical and contextual tailoring.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: April 21, 2025
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Journal: Melanoma research
Published: August 29, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 17, 2024
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.
Journal: Nature communications
Published: June 14, 2024
Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1.
Journal: Molecular therapy. Oncology
Published: March 25, 2024
Last Updated: 09/26/2026